Abstract | BACKGROUND: METHODS: RESULTS: In vitro, RzC cleaves HBV- RNA at its target site up to 30%, while the disabled ribozyme, dRzC, which has a one-base mutation in the catalytic site, did not cleave the target RNA at all. When the ribozymes were cotransfected into HepG2 cells with the HBV genome-containing plasmid, p3.6II, the inhibition of HBV replication by RzC was greater than that by dRzC, indicating that the active catalytic domain of the hammerhead ribozyme could increase the extent of antisense-mediated inhibition. In addition, there was a gradient of effectiveness in which the greater the amount of released ribozyme, the greater the reduction in HBV progeny DNA. CONCLUSIONS:
|
Authors | Y Feng, Y Y Kong, Y Wang, G R Qi |
Journal | Journal of gastroenterology and hepatology
(J Gastroenterol Hepatol)
Vol. 16
Issue 10
Pg. 1125-30
(Oct 2001)
ISSN: 0815-9319 [Print] Australia |
PMID | 11686839
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- RNA, Catalytic
- hammerhead ribozyme
|
Topics |
- Antiviral Agents
(metabolism, pharmacology)
- Blotting, Southern
- Dose-Response Relationship, Drug
- Drug Design
- Enzyme-Linked Immunosorbent Assay
- Hepatitis B virus
(drug effects, genetics)
- Humans
- Liver Neoplasms
(pathology)
- RNA, Catalytic
(genetics, metabolism, pharmacology)
- Transfection
- Tumor Cells, Cultured
- Virus Replication
(drug effects)
|